ArticleChemical & biomedical imaging2024
A Small Molecule Chemiluminophore with near 600 nm Emission for In Vivo Imaging of Myeloperoxidase and Inflammatory Diseases.
Article in Chemical & biomedical imaging, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Recent advances in chemiluminescence probes for Tumor microenvironment with applications in cancer diagnosis and therapy.Pharmaceutical science advances · 2026Review
- Dual-locked strategy for fluorescence/chemiluminescence dual-modal imaging reprogramming.Chemical science · 2026Article
- Recent Progress in Small Molecule-Based Chemiluminescent Probes for Reactive Oxygen and Nitrogen Species.Chemical & biomedical imaging · 2025Review
- Molecular Engineering of Direct Activated NIR-II Chemiluminescence Platform for In Vivo Chemiluminescence-fluorescence Duplex Imaging.Nature communications · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chemiluminescence has emerged as a vital tool for bioimaging in vivo. The red shift emission of chemiluminophores is extremely useful for in vivo bioimaging. In this work, the conjugation system of the luminol was extended to achieve a red-shifted emission (591 nm) along with excellent water solubility. The probe (HM-ASPH-PF) has a molecular weight of only 396.42, which contains a benzothiazole and a cyclic phthalhydrazide structure. The probe has been used for in vivo luminescence imaging of neutrophil-mediated acute liver injury, including alcoholic liver injury (ALI) and acute liver failure (ALF) in mice, by exploiting myeloperoxidase (MPO) as a biomarker. The activated neutrophils were specifically imaged by HM-ASPH-PF. HM-ASPH-PF was also successfully applied to monitor the neutrophils in livers in mouse models of ALI and ALF. Consequently, HM-ASPH-PF, as an effective luminescent small molecule that possesses a red-shift emission near 600 nm, has been applied for the detection of MPO in living cells and neutrophil-mediated acute liver injury. This work also demonstrates the applied potential of the luminescent probe for the diagnosis of other neutrophil-associated liver diseases.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.